MSDC 0602

Drug Profile

MSDC 0602

Alternative Names: MSDC-0602; MSDC-0602K

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Metabolic Solutions Development Company; Octeta Therapeutics
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Mitochondrial protein stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Preclinical Polycystic kidney disease
  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 01 Jul 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT02784444)
  • 18 May 2016 Octeta Therapeutics plans a phase II trial for Non-alcoholic fatty liver disease in USA (NCT02784444)
  • 13 Feb 2015 Suspended - Phase-II for Type-2 diabetes mellitus (In the elderly, In adults) in USA (PO) (MSDC communication)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top